Rationale and Design of EMPOWER, a Pragmatic Randomized Trial of Automated Hovering in Patients With Congestive Heart Failure

被引:10
|
作者
Mehta, Shivan J. [1 ,2 ,3 ]
Volpp, Kevin G. [1 ,2 ,3 ]
Asch, David A. [1 ,2 ,3 ]
Goldberg, Lee R. [1 ,2 ]
Russell, Louise B. [1 ,2 ]
Norton, Laurie A. [1 ,2 ]
Iannotte, Lauren G. [1 ,2 ]
Troxel, Andrea B. [4 ]
机构
[1] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Perelman Sch Med, Dept Hlth Policy & Med Eth, Philadelphia, PA 19104 USA
[3] Corporal Michael J Crescenz VA Med Ctr, Philadelphia, PA USA
[4] NYU, Sch Med, Dept Populat Hlth, Div Biostat, New York, NY USA
来源
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES | 2019年 / 12卷 / 04期
关键词
disease management; health care cost; heart failure; morbidity; mortality; HEALTH; HOSPITALIZATION; MANAGEMENT; ADHERENCE; OUTCOMES; RISK; MORTALITY; PATTERNS; SURVIVAL; MODEL;
D O I
10.1161/CIRCOUTCOMES.118.005126
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Congestive heart failure is a major cause of morbidity, mortality, and cost. Disease management programs have shown promise but lack firm evidence of effectiveness and scalability. We describe the motivation, design, and planned analyses of EMPOWER (Electronic Monitoring of Patients Offers Ways to Enhance Recovery), a randomized clinical trial of an innovative intervention incorporating behavioral economic principles with remote monitoring technology embedded within a healthcare system. METHODS AND RESULTS: EMPOWER is an ongoing, pragmatic, randomized clinical trial comparing usual care to an automated hovering intervention that includes patient-level incentives for daily weight monitoring and diuretic adherence combined with automated feedback into the clinical care pathway, enabling real-time response to concerning clinical symptoms. Identification of eligible patients began in May 2016, and implementation of the intervention is feasible. Trial processes are embedded into existing clinical pathways. The primary outcome is time to readmission for any cause. Cost-effectiveness analyses are planned to evaluate the healthcare costs and health outcomes of the approach. CONCLUSIONS: The EMPOWER trial incorporates leading-edge approaches in human motivation, derived from behavioral economics, with contemporary technology to provide scale and exception handling at low cost. The trial is also implemented within the naturalized environment of a health system, as much as possible taking advantage of the existing journeys of patients and workflows of clinicians. A goal of this pragmatic design is to limit resource utilization and also to test an intervention that would need minimal modification to be translated from research into a new way of practice.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Design and rationale for the Acute Congestive Heart Failure Urgent Care Evaluation: The ACUTE Study
    Lee, Douglas S.
    Lee, Jacques S.
    Schull, Michael J.
    Grimshaw, Jeremy M.
    Austin, Peter C.
    Tu, Jack V.
    AMERICAN HEART JOURNAL, 2016, 181 : 60 - 65
  • [42] Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study
    Krum, Henry
    Massie, Barry
    Abraham, William T.
    Dickstein, Kenneth
    Kober, Lars
    McMurray, John J. V.
    Desai, Ashkay
    Gimpelewicz, Claudio
    Kandra, Albert
    Reimund, Bernard
    Rattunde, Henning
    Armbrecht, Juergen
    EUROPEAN JOURNAL OF HEART FAILURE, 2011, 13 (01) : 107 - 114
  • [43] Randomized controlled trial of ventricular elastic support therapy in the treatment of symptomatic heart failure: Rationale and design
    Abraham, William T.
    Anand, Inder
    Aranda, Juan M., Jr.
    Boehmer, John
    Costanzo, Maria Rosa
    DeMarco, Teresa
    Holcomb, Richard
    Ivanhoe, Russell
    Kolber, Michael
    Rayburn, Barry
    AMERICAN HEART JOURNAL, 2012, 164 (05) : 638 - 645
  • [44] Rationale and design of the IRON-HF study: A randomized trial to assess the effects of iron supplementation in heart failure patients with anemia
    Beck-Da-Silva, Luis
    Rohde, Luis Eduardo
    Pereira-Barretto, Antonio Carlos
    De Albuquerque, Denilson
    Bocchi, Edimar
    Vilas-Boas, Fabio
    Moura, Lidia Zytynzki
    Montera, Marcelo W.
    Rassi, Salvador
    Clausell, Nadine
    JOURNAL OF CARDIAC FAILURE, 2007, 13 (01) : 14 - 17
  • [45] Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) Trial: Design, rationale and implementation
    Baraniuk, Sarah
    Tilley, Barbara C.
    del Junco, Deborah J.
    Fox, Erin E.
    van Belle, Gerald
    Wade, Charles E.
    Podbielski, Jeanette M.
    Beeler, Angela M.
    Hess, John R.
    Bulger, Eileen M.
    Schreiber, Martin A.
    Inaba, Kenji
    Fabian, Timothy C.
    Kerby, Jeffrey D.
    Cohen, Mitchell Jay
    Miller, Christopher N.
    Rizoli, Sandro
    Scalea, Thomas M.
    O'Keeffe, Terence
    Brasel, Karen J.
    Cotton, Bryan A.
    Muskat, Peter
    Holcomb, John B.
    INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED, 2014, 45 (09): : 1287 - 1295
  • [46] A randomized double-blind trial of an interventional device treatment of functional mitral regurgitation in patients with symptomatic congestive heart failure-Trial design of the REDUCE FMR' study
    Goldberg, Steven L.
    Meredith, Ian
    Marwick, Thomas
    Haluska, Brian A.
    Lipiecki, Janusz
    Siminiak, Tomasz
    Mehta, Nawzer
    Kaye, David M.
    Sievert, Horst
    AMERICAN HEART JOURNAL, 2017, 188 : 167 - 174
  • [47] A comparison of Gordon's functional health patterns model and standard nursing care in symptomatic heart failure patients: A randomized controlled trial
    Turen, Sevda
    Enc, Nuray
    APPLIED NURSING RESEARCH, 2020, 53
  • [48] The heart failure revascularisation trial (HEART): rationale, design and methodology
    Cleland, JGF
    Freemantle, N
    Ball, SG
    Bonser, RS
    Camici, P
    Chattopadhyay, S
    Dutka, D
    Eastaugh, J
    Hampton, J
    Large, S
    Norell, MS
    Pennell, DJ
    Pepper, J
    Sanda, S
    Senior, R
    Smith, D
    EUROPEAN JOURNAL OF HEART FAILURE, 2003, 5 (03) : 295 - 303
  • [49] Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction The EMPEROR-Reduced Trial
    Packer, Milton
    Anker, Stefan D.
    Butler, Javed
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Pocock, Stuart J.
    Carson, Peter
    Anand, Inder
    Doehner, Wolfram
    Haass, Markus
    Komajda, Michel
    Miller, Alan
    Pehrson, Steen
    Teerlink, John R.
    Brueckmann, Martina
    Jamal, Waheed
    Zeller, Cordula
    Schnaidt, Sven
    Zannad, Faiez
    CIRCULATION, 2021, 143 (04) : 326 - 336
  • [50] The STARBRITE Trial: A Randomized, Pilot Study of B-Type Natriuretic Peptide-Guided Therapy in Patients With Advanced Heart Failure
    Shah, Monica R.
    Califf, Robert M.
    Nohria, Anju
    Bhapkar, Manju
    Bowers, Margaret
    Mancini, Donna M.
    Fluzat, Mona
    Stevenson, Lynne W.
    O'Connor, Christopher M.
    JOURNAL OF CARDIAC FAILURE, 2011, 17 (08) : 613 - 621